Dantrolene Sodium for Injection supply in Canada: Notice
Date published: July 21, 2025
Date updated: October 31, 2025
On this page
Background
Dantrolene Sodium for Injection is used in hospitals to manage malignant hyperthermia crisis, a life-threatening reaction to certain anesthesia medications.
In Canada, Dantrolene Sodium for Injection is marketed in vials by Hikma Canada Limited and Endo Operations Ltd. Hikma is reporting a shortage until March 1, 2026, due to a manufacturing disruption.
To help mitigate the impact of this shortage, we worked with Hikma to extend the expiry date for the current inventory of Dantrolene Sodium for Injection.
- Lot 2309064.1 has a labelled expiry date of June 2025. The expiry date for this lot has been extended to March 2026.
What we're doing
We recognize the importance of Dantrolene Sodium for Injection. Ensuring continued access is a top priority.
We're communicating with provincial and territorial governments and other stakeholders, such as the Canadian Society of Healthcare-Systems Pharmacy, to coordinate the sharing of information about the shortage.
What you can do
Check this webpage regularly as we will update it if new information becomes available.
Learn more about drug shortages in Canada and how Canadians can deal with drug shortages.